Actively Recruiting
Optimizing Treatment on Idiopathic Inflammatory Myopathies
Led by University of Sao Paulo · Updated on 2024-12-05
60
Participants Needed
1
Research Sites
1039 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
As a T2T, our patients with idiopathic inflammatory myopathies will receive pulse therapies with methyprednisolone and/or human intravenous immunoglobulin, or only methyprednisolone at disease onset. This scheme is an internal routine protocol of our Service.
CONDITIONS
Official Title
Optimizing Treatment on Idiopathic Inflammatory Myopathies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with idiopathic inflammatory myopathies
You will not qualify if you...
- Diagnosis of inclusion body myositis
- Diagnosis of muscular dystrophies
- Diagnosis of neoplasia-associated myopathies
- Diagnosis of overlapped myopathies
- Diagnosis of other myopathies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Samuel Katsuyuki Shinjo
São Paulo, Brazil, 01246903
Actively Recruiting
Research Team
S
Samuel K Shinjo, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here